SCHEMBL195501

SCHEMBL195501

CC(C)(C)[Si](C)(C)OCc1cccc(N2CCCC2)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AGXT P21549 3/20 0.62
PRMT6 Q96LA8 1/20 0.50
USP14 P54578 1/20 0.40
L3MBTL3 Q96JM7 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
MBTD1 Q05BQ5 1/20 0.39
TP53BP1 Q12888 1/20 0.39
CACNA2D1 P54289 2/20 0.39
SLC6A2 P23975 1/20 0.39
AOC3 Q16853 3/20 0.39
HCRTR1 O43613 5/20 0.38
HCRTR2 O43614 5/20 0.38
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
USP2 O75604 1/20 0.38
ALDH1A1 P00352 1/20 0.38
POLB P06746 1/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
BLM P54132 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15000826 0.88 ADRB1 (0.49) AGXTALDH1A1MAPT
SCHEMBL15000570 0.85 AOC3 (0.55) AGXTAOC3KDM4EPOLB
SCHEMBL14993608 0.83 AOC3 (0.57) AGXTAOC3KDM4EALDH1A1POLB
SCHEMBL15505087 0.82 AGXT (0.43) AGXTL3MBTL3L3MBTL1MBTD1TP53BP1
SCHEMBL15000490 0.81 GPR119 (0.50) AGXTMEN1ALDH1A1MAPTKMT2A
SCHEMBL15000567 0.81 AGXT (0.44) AGXTL3MBTL1AOC3KDM4EPOLB
SCHEMBL15000566 0.80 AGXT (0.55) AGXTAOC3ALDH1A1MAPTHPGD
SCHEMBL19240350 0.80 AGXT (0.65) AGXTPRMT6L3MBTL3L3MBTL1MBTD1
SCHEMBL15000518 0.78 AOC3 (0.43) AGXTAOC3KDM4EMAPT
SCHEMBL19251341 0.77 AGXT (0.71) AGXTPRMT6L3MBTL3L3MBTL1MBTD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8754100-B2 Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors EISAI R&D MANAGEMENT CO., LTD. (JP) 2014-06-17 US disclosed
EP-2615090-A1 Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors Eisai R&D Management Co., Ltd. (JP) 2013-07-17 EP disclosed
EP-2401276-B1 NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS EISAI R&D MAN CO LTD (JP) 2013-06-05 EP disclosed
US-20120053171-A1 Nitrogen-Containing Fused Heterocyclic Compounds and Their use as Beta Amyloid Production Inhibitors EISAI R&D MANAGEMENT CO., LTD., (JP) 2012-03-01 US disclosed
EP-2401276-A1 NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS Eisai R&D Management Co., Ltd. (JP) 2012-01-04 EP disclosed
WO-2010098487-A1 NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053171-A1 Nitrogen-Containing Fused Heterocyclic Compounds and Their use as Beta Amyloid Production Inhibitors BACE1, APP, PSEN1 AGXT 270/4885PRMT6 337/4885USP14 4295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.